- Pre-order Price Guarantee! Order now and if the Amazon.com price decreases between your order time and the end of the day of the release date, you'll receive the lowest price. Here's how (restrictions apply)
- Save $10 when you spend $50 or more when you pay with Bill Me Later®. Offer valid Oct 13, 2008 - Dec 30, 2008. Limited to items sold by Amazon.com. Subject to credit approval. One per customer. Enter code BMLSAVES at checkout. Here's how (restrictions apply)
Join Amazon Prime and ship Two-Day for free and Overnight for $3.99. Already a member? Sign in.
 |
 |
 |
|
Save all season long on bestsellers, kids' books, holiday favorites and more in our Books Holiday Store. |
|
 |
|
 |
Special Offers and Product Promotions
Editorial Reviews
Product Description
About the Author
Lalitha Nagarajan is an Associate Professor, Department of Molecular Genetics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
About the Author
Lalitha Nagarajan is an Associate Professor, Department of Molecular Genetics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Product Details
Would you like to update product info or give feedback on images?
|